Last reviewed · How we verify

CBT-004 — Competitive Intelligence Brief

CBT-004 (CBT-004) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: T cell engager / Bispecific antibody. Area: Oncology.

phase 2 T cell engager / Bispecific antibody Oncology Small molecule Live · refreshed every 30 min

Target snapshot

CBT-004 (CBT-004) — Cloudbreak Therapeutics, LLC. CBT-004 is a T cell engager designed to redirect patient T cells to recognize and eliminate cancer cells expressing a specific tumor antigen.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CBT-004 TARGET CBT-004 Cloudbreak Therapeutics, LLC phase 2 T cell engager / Bispecific antibody

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (T cell engager / Bispecific antibody class)

  1. Cloudbreak Therapeutics, LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CBT-004 — Competitive Intelligence Brief. https://druglandscape.com/ci/cbt-004. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: